Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Facts Views Vis Obgyn ; 16(1): 75-81, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38551477

RESUMO

Background: Regardless of the technique used, extraction of the uterus is a crucial step in hysterectomy. There is currently no scoring system to predict its feasibility. Objectives: Our main objective was to determine a predictive score of uterine extraction feasibility to optimise surgical planning of total hysterectomy. As secondary objectives, we examined the correlation between uterine volume predicted by preoperative ultrasound and the final weight of the surgical specimen and analysed the impact of the uterine extraction modality on operative and hospitalisation times. Materials and Methods: We defined a Uterine Extraction Score (UES) based on the ratio between uterine sizes and vaginal access. This score was retrospectively applied to a cohort of 178 patients who were hysterectomised for benign conditions between January 2019 and December 2022. Main outcome measures: The UES allows identification of three groups of decreasing feasibility of vaginal extraction, symbolised by traffic light colours: green - vaginal extraction without morcellation, orange -vaginal extraction with morcellation, red - abdominal morcellation by mini-laparotomy or primary laparotomy. Results: The results show that the UES--predicted, and the observed routes of extraction concord in 92% of cases. There is a strong correlation between estimated volume and final uterine weight. Uterine morcellation lengthens the operative time and the hospital stay. Conclusions: The UES seems to be a reliable tool to predict the route of uterine extraction in total hysterectomy. What is new?: The development of a new scoring system empowers surgeons with decisive information to enhance perioperative outcomes.

2.
Eur J Surg Oncol ; 50(3): 108012, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38350264

RESUMO

BACKGROUND: The standard treatment for gestational choriocarcinoma is chemotherapy. OBJECTIVE: To describe the risk of recurrence with expectant management of gestational choriocarcinoma that has reached a normal human chorionic gonadotropin level after tumor removal without adjuvant chemotherapy. METHODS: A retrospective multicenter international cohort study was conducted from 1981 to 2017 involving 11 gestational trophoblastic disease reference centers with patient's follow-up extended until 2023. Clinical and biological data of included patients were extracted from each center's database. The inclusion criteria were i) histological diagnosis of gestational choriocarcinoma in any kind of placental tissue retrieved, ii) spontaneous normalization of human chorionic gonadotropin level following choriocarcinoma retrieval, iii) patient did not receive any oncological treatment for the choriocarcinoma, iv) and at least 6 months of follow-up after the first human chorionic gonadotropin level normalization. RESULTS: Among 80 patients with retrieved gestational choriocarcinoma and whose human chorionic gonadotropin level normalized without any other oncological therapy, none had a recurrence of choriocarcinoma after a median follow-up of 50 months. The median interval between choriocarcinoma excision and human chorionic gonadotropin level normalization was 48 days. The International Federation of Gynecology and Obstetrics/World Health Organization risk score was ≤6 in 93.7% of the cases. CONCLUSIONS: This multicenter international study reports that selected patients with gestational choriocarcinoma managed in gestational trophoblastic disease reference centers did not experience any relapse when the initial tumor evacuation is followed by human chorionic gonadotropin level normalization without any additional treatment. Expectant management may be a safe approach for highly selected patients.


Assuntos
Coriocarcinoma , Doença Trofoblástica Gestacional , Neoplasias Uterinas , Humanos , Gravidez , Feminino , Estudos de Coortes , Gonadotropina Coriônica/uso terapêutico , Recidiva Local de Neoplasia , Placenta/patologia , Doença Trofoblástica Gestacional/tratamento farmacológico , Doença Trofoblástica Gestacional/cirurgia , Doença Trofoblástica Gestacional/patologia , Coriocarcinoma/tratamento farmacológico , Neoplasias Uterinas/tratamento farmacológico , Neoplasias Uterinas/cirurgia
3.
Rev Med Liege ; 75(1): 6-9, 2020 Jan.
Artigo em Francês | MEDLINE | ID: mdl-31920037

RESUMO

Velamentous cord insertion is a rare placental abnormality, that may be associated with vasa praevia, i.e. the presence of an umbilical vessel near the internal cervical orifice. In case of spontaneous rupture of the membranes, there is a major risk of fetal haemorrhage, which is often lethal for the unborn baby. The challenge of care is based on the prenatal diagnosis during the 2nd trimester ultrasound. In case a vasa praevia is confirmed during the 3rd trimester, elective caesarean section should be carried out prior to the onset of labour, between 34 and 36 weeks of pregnancy. Corticosteroid treatment for fetal lung maturation is recommended at 32 weeks of gestation because of the increased risk of preterm delivery. Velamentous cord insertion may be associated with other adverse pregnancy outcomes such as intrauterine growth restriction, death in utero, placental abnormalities.


L'insertion vélamenteuse du cordon ombilical est une anomalie placentaire rare, pouvant être associée à un vasa praevia, c'est-à-dire la présence d'un vaisseau ombilical en regard de l'orifice interne du col utérin. En cas de rupture spontanée des membranes, le risque d'hémorragie fœtale est majeur et, le plus souvent, létal pour l'enfant à naître. Le défi de la prise en charge est le diagnostic anténatal à l'échographie du 2ème trimestre. En cas de vasa praevia confirmé lors du 3ème trimestre, une césarienne doit être programmée avant la mise en travail spontanée, aux alentours de 34-36 semaines d'aménorrhée. Une cure de maturation pulmonaire par corticostéroïdes est recommandée à 32 semaines d'aménorrhée en raison du risque accru de prématurité. L'insertion vélamenteuse du cordon peut être associée à d'autres complications périnatales telles qu'un retard de croissance intra-utérin, une mort fœtale in utero, des anomalies placentaires.


Assuntos
Cesárea , Vasa Previa , Feminino , Humanos , Recém-Nascido , Gravidez , Resultado da Gravidez , Diagnóstico Pré-Natal , Ultrassonografia Pré-Natal , Vasa Previa/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...